Awaiting development: Guidance and quality standards
Showing 1 to 8 of 8
| Title | Type |
|---|---|
| Aquablation robotic therapy for lower urinary tract symptoms caused by benign prostatic hyperplasia | Medical technologies guidance |
| Bimekizumab for treating ankylosing spondylitis [ID4011] | Technology appraisal guidance |
| Daratumumab for treating high-risk smouldering multiple myeloma [ID6214] | Technology appraisal guidance |
| Doxecitine–doxribtimine for treating thymidine kinase 2 deficiency in people of any age who had symptoms before 13 years [TSID12046] | Technology appraisal guidance |
| Remibrutinib for treating chronic spontaneous urticaria inadequately controlled by H1-antihistamines in people 12 to 17 years [ID6649] | Technology appraisal guidance |
| Sabizabulin for treating COVID 19 [TSID11814] | Technology appraisal guidance |
| Subcutaneous mosunetuzumab for treating relapsed or refractory follicular lymphoma after 2 or more treatments TSID 12081 | Technology appraisal guidance |
| Vilobelimab for treating COVID 19 [TSID11815] | Technology appraisal guidance |